Media ReleasesCircadian

View All Circadian News

CEO on IND status for VGX-100

In this Open Briefing, CEO & MD Robert Klupacs discusses

- Clinical and commercial implications of IND status for VGX-100
- Design, end points and time lines of Phase I trials
- Outlook and value points for Circadian shareholders

For further information please download PDF below:

Download this document